Rossmax International Ltd. AI Stock Analysis
Rossmax International Ltd. (4121) AI Stock Analysis
Rossmax International Ltd.
(TPEx:4121)
The stock scores at the bottom of the range due to a convergence of severe fundamental and market risks. The most significant factor is the company's rapidly deteriorating financial performance, marked by a sharp revenue decline and sustained losses. This is compounded by a bearish technical profile, with the stock in a clear downtrend and showing no signs of momentum reversal. The negative P/E ratio further underscores the lack of earnings-based value. The only mitigating factor is the company's ability to generate positive operating cash flow, but this is not enough to offset the overwhelming negative signals.
Rossmax International Ltd. (4121) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.01B
- Dividend Yield
- ―
- Average Volume (3M)
- 46.43K
- Price to Earnings (P/E)
- -25.0
- Beta (1Y)
- 0.54
- Revenue Growth
- 0.08%
- EPS Growth
- -10.61%
- Country
- TW
- Employees
- 350
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
Rossmax International Ltd. Business Overview & Revenue Model
Company Description
Rossmax International Ltd. is dedicated to creating and delivering a wide array of healthcare products and solutions. Their diverse product lineup includes advanced diagnostic and monitoring devices such as body composition scales, which provide read...
Rossmax International Ltd. Financial Statement Overview
Summary
Financial performance is severely strained. The income statement shows a 48.9% revenue drop and persistent net losses, while the balance sheet reflects eroding equity. Positive operating cash flow provides a slight buffer, but the overall trajectory is negative.
Income Statement
18Very NegativeBalance Sheet
42NeutralCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.78B | 3.80B | 3.85B | 3.81B | 4.34B | 3.95B |
| Gross Profit | 1.20B | 968.71M | 1.33B | 1.27B | 1.51B | 1.30B |
| EBITDA | 165.90M | 269.74M | 307.86M | 347.12M | 581.56M | 425.88M |
| Net Income | -54.57M | -29.90M | -29.35M | -6.67M | 170.27M | 111.37M |
Balance Sheet | ||||||
| Total Assets | 4.00B | 4.21B | 4.23B | 4.09B | 3.99B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 701.04M | 839.39M | 774.70M | 691.27M | 816.49M | 916.66M |
| Total Debt | 1.27B | 1.34B | 1.29B | 1.39B | 1.12B | 1.08B |
| Total Liabilities | 2.09B | 2.22B | 2.14B | 2.24B | 2.05B | 1.98B |
| Stockholders Equity | 1.38B | 1.41B | 1.48B | 1.44B | 1.55B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | 181.08M | 236.74M | 238.54M | 195.01M | 299.54M | 225.60M |
| Operating Cash Flow | 231.55M | 284.20M | 314.10M | 302.35M | 434.21M | 575.43M |
| Investing Cash Flow | -97.98M | -45.71M | -74.69M | -107.80M | -137.20M | -347.69M |
| Financing Cash Flow | -207.83M | -217.55M | -131.49M | -216.34M | -396.22M | -150.60M |
Rossmax International Ltd. Peers Comparison
Overall Rating
TW:624261Neutral
TW:419842Neutral- TW:412137Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6242 | 61Neutral | TWD 1.07B | 13.90 | ― | 5.97% | -0.93% | -10.65% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4198 | 42Neutral | TWD 1.10B | -28.07 | ― | ― | ― | ― |
| TW:4121 | 37Underperform | TWD 1.01B | -25.02 | ― | ― | 0.08% | -10.61% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4121 | Rossmax International Ltd. | 12.20 | -3.10 | -20.26% | |
| TW:4194 | Holy Stone Healthcare Co., Ltd. | 6.25 | -1.93 | -23.59% | |
| TW:4198 | S&S Healthcare Holding Ltd. | 46.75 | 8.75 | 23.03% | |
| TW:4431 | Mytrex Health Technologies, Inc. | 21.50 | 4.00 | 22.86% | |
| TW:6242 | LI KANG BIOMEDICAL Co. Ltd. | 32.00 | -4.86 | -13.19% | |
| TW:6543 | Perfect Medical Industry Co., Ltd. | 17.00 | -10.51 | -38.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026